7 results about "Senile osteopenia" patented technology

The invention relates to the technical field of biological medicines, in particular to application of hsacirc0008126 in prevention and treatment of senile osteoporosis. The invention provides the circular RNA hsacirc0008126 which can be used for regulating and controlling the mesenchymal stem cell osteogenesis and adipogenic differentiation, the mechanism of the circular RNA hsacirc0008126 on the mesenchymal stem cell osteogenesis and adipogenic differentiation is different from that of the prior art, the medicine taking the circular RNA hsacirc0008126 as the target spot can be used for treating and / or preventing osteoporosis, and the circular RNA hsacirc0008126 has important application value.

The invention relates to the technical field of rehabilitation medical treatment and human-computer interaction, and discloses a rehabilitation method for senile osteoporosis with cognitive impairment based on augmented reality. The method comprises the steps that movement and physiological data of a patient are collected, a synchronous calibration signal is obtained through a fusion algorithm and Kalman filtering, and a virtual and real environment deviation value is determined in combination with the rehabilitation progress and pain feedback; optimizing response parameters and real-time force feedback parameters of the virtual scene through an adaptive adjustment mechanism, and extracting dynamic demand characteristics of the patient; fusing the dynamic demand features, audiovisual, tactile and interaction delay data through a convolutional neural network to obtain a virtual-real interaction feedback sequence; and generating virtual scene update data and an auxiliary device supporting force simulation value based on the sequence, and synthesizing a rehabilitation training output signal. According to individual requirements of patients, accurate virtual environments and interactive feedback are provided, dynamic accurate matching of virtual and real environments and real-time adaptation of multi-modal feedback in rehabilitation training are achieved, and the immersion feeling and rehabilitation effect of training are improved.

The invention relates to application of a TRMT10C agonist TM3 in preparation of a medicine for treating senile osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the TRMT10C agonist TM3 is used for treating senile osteoporosis for the first time. A mouse experiment verifies that the TRMT10C agonist TM3 can inhibit bone loss of a mouse with osteoporosis, increase the bone density, the number of bone trabecula and the volume fraction of the bone trabecula, reduce the separation degree of the bone trabecula and promote bone formation. It is fully proved that the TRMT10C agonist TM3 can be used for treating the senile osteoporosis caused by the fact that the osteogenesis rate is remarkably reduced due to age increase, and therefore the TRMT10C agonist TM3 can be used for preparing the medicine for treating the senile osteoporosis and has important significance in clinical treatment of the senile osteoporosis in the future.

The application discloses application of black corn polysaccharide in preparation of a medicine for preventing or treating senile osteoporosis. The evaluation of the prevention or treatment effect of the black corn polysaccharide on senile osteoporosis includes improvement effects on serum bone metabolism markers, bone microstructure and bone biomechanics. The black corn polysaccharide of the application refers to a polysaccharide powder after water extraction, alcohol precipitation, Sevag method deproteinization, H2O2 method depigmentation and dialysis bag dialysis from dried black corn kernels. The black corn polysaccharide has improvement effects on imbalance of serum bone metabolism markers of senile osteoporosis, deterioration of bone microstructure and decrease of bone strength. The results show that the black corn polysaccharide has great improvement effects on bone loss in preventing senile osteoporosis. Therefore, the black corn polysaccharide has important significance in developing senile osteoporosis in clinic.

The invention provides a movable fixing device for senile osteoporosis spinal fracture, and relates to the technical field of fracture fixtion.The movable fixing device for senile osteoporosis spinal fracture comprises a seat body, a patient sits on a seat plate, a lifting rod is clamped under the armpit, and a lifting driving part can drive the lifting rod to move upwards; when the lifting rods are lifted, the two limiting columns can rotate to the position between the two lifting rods, the two limiting columns are connected and fixed through the connecting part, the translation driving part drives the limiting columns to move towards the patient, and therefore the patient can be lifted upwards, and the spine and the vertebra of the patient can be prevented from being pressed. The limiting columns can clamp the upper body of the patient under the cooperation of the limiting columns and the backup plate, so that the spine of the patient can be fixed to the backup plate, the effect of fixing the spine is achieved, and in conclusion, in the process of guaranteeing healing and rehabilitation of the patient, the device can move outdoors to adjust the mental health of the patient.

The present application provides a kind of lignan composition for resisting osteoporosis and its application, the composition is composed of pinoresinol diglucoside, dehydrodiconiferyl alcohol-4, γ'-bis-O-β-D-glucopyranoside, pinoresinol monoglucoside component;The mass ratio of pinoresinol diglucoside: dehydrodiconiferyl alcohol-4, γ'-bis-O-β-D-glucopyranoside: pinoresinol monoglucoside is 1:0.1-0.3:0.2-0.4.The lignan composition provided by the present application is stable in quality, high in safety, suitable for long-term taking, and has good effect on treating osteoporosis.The composition can be used for senile osteoporosis, and has more significant effect on inhibiting bone density reduction in ovary-removed female rat osteoporosis model.

The application discloses an inflammation-targeted Prussian blue nanolipase and a preparation method and application thereof, and the nanolipase can be used for preparing a drug for treating senile osteoporosis and age-related diseases, and the nanolipase comprises a macrophage membrane and citric acid modified Prussian blue nanoparticles wrapped in the macrophage membrane, the method comprises the following steps: preparing the citric acid modified Prussian blue nanoparticles, extracting the macrophage membrane, mixing a solution of the Prussian blue nanoparticles and a suspension of the macrophage membrane and carrying out ultrasonic treatment, and carrying out solid-liquid separation after stirring. The application solves the problems of short half-life and poor targeting of the existing nanolipase for treating osteoporosis, reduces off-target toxicity and enhances the stability of the curative effect, the nanolipase can more efficiently remove active oxygen, inhibit osteoclast differentiation, relieve bone loss and does not affect osteogenesis, and the nanolipase realizes long-acting, safe and efficient osteoporosis treatment as a whole, and has the application potential of being expanded to other age-related inflammatory diseases.